This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TEM Continues to Strengthen Its Genomics Leadership With New Products
by Sridatri Sarkar
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verastem (VSTM) delivered earnings and revenue surprises of -164.71% and +82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Verastem (VSTM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
by Kinjel Shah
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Best Momentum Stocks to Buy for Oct. 21
by Zacks Equity Research
VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.
New Strong Buy Stocks for Oct. 21: NEM, AS and More
by Zacks Equity Research
NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
by Zacks Equity Research
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.